| 生物活性 | Strictinin is an orally active phenolic compound that reduces xanthine oxidase activity, uric acid production, and the activation of ERK1/2, JNK, NF-κB, and NLRP3 inflammasome components in Xanthine (MS-L85792)-treated hepatocytes, and also lowers the elevated serum uric acid levels and enhanced xanthine oxidase activity in potassium oxonate-treated mice; as a ROR1 inhibitor, Strictinin exhibits anticancer activity against highly aggressive androgen-independent prostate cancer by inducing apoptosis, blocking the cell cycle, and inhibiting cancer cell migration, invasion, and epithelial-mesenchymal transition; moreover, Strictinin can modulate gut microbiota, inhibit bacterial growth and biofilm formation, accelerate small intestinal transit, and block viral entry and replication, and is therefore applicable to research on hyperuricemia, androgen receptor-negative androgen-independent prostate cancer, triple-negative breast cancer, bacterial infection, constipation, coronavirus infection, dental caries, and influenza A, influenza B, and human parainfluenza virus type 1 infections. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 体外研究 (In Vitro) |
Strictinin (50-500 μM; 24 h) 仅在 500 μM 浓度下对 AML12 小鼠肝细胞表现出细胞毒性。 Cell Cytotoxicity Assay
Western Blot Analysis
Cell Viability Assay
Apoptosis Analysis
Western Blot Analysis
Cell Migration Assay
Cell Invasion Assay
Cell Cycle Analysis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 体内研究 (In Vivo) |
Strictinin (400-1000 mg/kg;灌胃;每周 1 次;共 7 天) 可通过抑制肝脏黄嘌呤氧化酶活性、降低血清尿酸水平、保护肾脏免受损伤以及调节肠道菌群使其趋于更健康的组成,显著减轻氧酸钾诱导的雄性 ICR 小鼠高尿酸血症。
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 性状 | 固体 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 颜色 | White to off-white |
| 分子量 | 634.45 |
| 分子式 | C27H22O18 |
| CAS No. | 517-46-4 |
| 储存方式 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
溶液配制表
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
H2O 中的溶解度 : 50 mg/mL (78.81 mM; 超声助溶)
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。